Aims: To perform a systematic review of screening for preeclampsia (PE) with the combination of uterine artery Doppler (UAD), maternal history, mean arterial pressure and/or maternal serum markers. Methods: We identified eligible studies through a search of Medline, and, for each included study, we assessed the risk of bias and extracted relevant data. We reported the performance of screening tests according to the target population (low-or high-risk), the trimester of screening (first and/or second) and the subset of PE screened for (early and late). Results: Several tests provided moderate or convincing prediction of early PE, but screening for late PE was poor. Although UAD is more accurate in the second trimester, we found encouraging results for first-trimester screening when it was combined with other markers. Performance of screening was consistently lower in populations with risk factors for PE in the maternal history. Conclusions: We present encouraging results for the prediction of early PE, even in the first trimester of pregnancy. The different performance of tests in screening for early vs. late PE, and of low-vs. high-risk populations, supports the concept that PE is a heterogeneous disease.
Introduction
Pre-eclampsia (PE) affects 2-8% of pregnancies and is a major cause of maternal and perinatal morbidity and mortality w45x. In mothers, PE may lead to disseminated coagulopathy, pulmonary edema, renal or liver failure, eclampsia, stroke and placental abruption w38x. In fetuses, it may cause intrauterine growth restriction (IUGR), hypoxianeurologic injury and preterm delivery w38x. Ultimately, PE may lead to death of the mother and/or the fetus w38x.
Considering the impact of PE in obstetrics, the development of an accurate screening method would be of great value. Although, at present, there is no effective preventive intervention for PE w38, 45x, screening would allow us to select a group of pregnant women who would receive increased maternal and fetal monitoring w12x. From a research point of view, it would be essential for future development of effective prophylactic measures, as it would enable the recruitment of high-risk women in which the effect of those measures could be evaluated w12x.
Classically, PE has been associated with inadequate trophoblast invasion of the spiral arteries and consequent failure of development of a low-resistance uteroplacental circulation that characterizes normal pregnancies w10, 13x. Therefore, uterine artery Doppler (UAD) has been extensively studied as a screening test for PE. A recent meta-analysis w11x reported that a high second-trimester pulsatility index (PI) detects 42% of PE cases with a specificity (Sp) of 91%. In the first trimester, the accuracy is lower, with a sensitivity (Sn) of 25% and a Sp of 95%.
The National Institute for Health and Clinical Excellence w24x currently recommends the assessment of each woman's risk for PE on the basis of maternal history. Age G40 years, body mass index G30 kg/m 2 , pre-existing vascular or renal disease, nulliparity or pregnancy interval of )10 years, prior or family history of PE and multiple pregnancy increase the probability of developing PE. However, accuracy of screening with maternal history alone is low w32x.
In addition to UAD and maternal history, a large number of maternal serum markers have been investigated for the prediction of PE, but their use as single screening tests has also been disappointing w6x. Finally, early measurement of mean arterial pressure (MAP) is another screening test that should not be forgotten because it is simple and inexpensive and appears to be an important predictor of subsequent PE w6x.
Despite great research efforts, in 2004 the World Health Organization w12x concluded that no single test was yet available to provide accurate screening for PE. Since then, there has been growing interest in the combination of markers for PE screening. Recently, this was reviewed by Giguère et al. w17x , who concluded that the combination of biochemical and ultrasonographic markers improves prediction of PE. However, the authors did not systematically evaluate the contribution of maternal history and MAP to combined screening.
In this context, we performed the current systematic review to evaluate first-and second-trimester screening for PE with tests that combine UAD with maternal history, MAP and/or maternal serum markers. Table 1 Inclusion and exclusion criteria used to determine eligibility of the studies for the systematic review.
Inclusion criteria 1. Study design
Prospective studies, in which screening tests were applied before outcomes were developed, including cohort and nested case-control studies Rationale A case-control design may represent a valid alternative to a cohort analysis if cases and controls belong to a common reference population; otherwise, selection bias may ensue. This is assured when participants are selected from a well-defined cohort, as in nested case-control studies, which take advantage of ''both the methodologic soundness of the cohort design (i.e., limiting selection bias) and the efficiency of the case-control approach'' (limiting costs) w47x 7. Reference standard Several definitions of PE were accepted, as long as they included the concurrent presence of hypertension and proteinuria Several definitions of early PE were accepted, but the preferred one was: PE requiring delivery before 34 weeks' gestation. When other definitions were considered, they were specified Rationale
The selection of the preferred definition of early PE was based on the following facts: (1) the administration of glucocorticoids is recommended for fetal lung maturity when there is risk of preterm delivery in pregnant women with -34 weeks' gestation w18x; (2) preterm birth occurring after 34 weeks' gestation is rarely associated with mortality or major morbidity w18x
Exclusion criteria
The definition of PE considered in the study was not reported PE was combined with other pregnancy complications in the outcome PEspre-eclampsia, UADsuterine artery Doppler, MAPsmean arterial pressure, PAPP-Aspregnancy-associated plasma protein-A, hCGshuman chorionic gonadotropin, AFPsa-fetoprotein, PP13splacental protein 13, PlGFsplacental growth factor, sFlt1ssoluble fmslike tyrosine kinase 1.
Methods
A search was conducted in the Medline database using the following MeSH terms or keywords, with no limits: preeclampsia, pre-eclampsia, diagnosis, screening, prediction, uterine artery, Doppler, clinical, maternal, characteristics, factors, history, blood pressure, pregnancyassociated plasma protein-A, PAPP-A, chorionic gonadotropin, hCG, alpha-fetoprotein, inhibin A, activin A, placental protein 13, placental growth factor, soluble fms-like tyrosine kinase 1, soluble vascular endothelial growth factor receptor-1. Additional keywords were tested but were not included in the final query because they did not improve the sensitivity of the search. Table 1 presents the selection criteria used to determine the eligibility of the studies identified by the search, and, when appropriate, the rationale for using those criteria. They were applied in two stages: first, to the titles and abstracts of the articles yielded by the query; second, to the full texts of the articles selected in the first stage.
The reference list of the selected articles was also searched to identify additional potential articles of interest, which were then retrieved and submitted to the selection criteria.
The search was updated periodically and was last run on December 10, 2010. Relevant data were extracted from each article using a standardized form. Risk of bias was assessed according to criteria that had been previously used w12x and that we adapted to our own review (Table 2 ). In nested case-control studies, we considered selection adequate when cases included ''all (or a representative sample of) individuals with the outcome of interest occurring in the defined cohort'' and controls were ''a random sample of the individuals remaining in the cohort'' w47x. This way, investigators ensured that cases were representative of individuals with the outcome in the population studied and that controls were representative of individuals without the outcome in the same population.
When available, we reported the following measures of accuracy: area under the receiver operating charactreistic (ROC) curve (AUC), Sp, Sn, and likelihood ratios of the positive (LRq) and negative (LR-) results. The LRq is defined as Sn/(1-Sp) and the LR-as (1-Sn)/Sp w12x. Convincing prediction is provided by tests with Table 2 Criteria for assessment of risk of bias.
Selection of study participants Adequate
• Cohort studies in which all eligible women were included consecutively or randomly into the study • Nested case-control studies in which all eligible women were included consecutively or randomly into the original cohort, all or a random selection of the participants that developed PE in the original cohort were included as cases, and a random selection of the unaffected participants of the original cohort were included as controls Inadequate
• Studies which did not meet at least one of the above-mentioned criteria Unreported
• It was not possible to draw a conclusion based on the information reported in the article 2. Description of the study population Adequate • Two or more of the following characteristics were described: women's age, parity, underlying diseases or the risk status of the population (low or high) Inadequate
• Only one or none of the above-mentioned characteristics was reported 3. Description of the screening tests Adequate • Cut-off levels, clear definitions of positive and negative test results, and gestational age at which the screening tests were performed were mentioned in the text Inadequate
• Absence of any of the above-mentioned information in the report 4. Blinding of the readers of the screening tests Adequate • Readers of all the screening tests were masked to the results of the reference standard Inadequate
• Readers of at least one of the screening tests were not masked to the results of the reference standard Unreported
• It was not possible to draw a conclusion based on the information reported in the article 5. Blinding of the readers of the reference standard Adequate • The results of the screening tests were not communicated to the managing clinicians and readers of the reference standard were masked to the results of the screening tests Inadequate
• The results of at least one of the screening tests were communicated to the managing clinicians or readers of the reference standard were not masked to the results of the screening tests Unreported
• It was not possible to draw a conclusion based on the information reported in the article 6. Follow-up and verification Adequate • At least 90% of the participants originally subjected to the screening tests were followed up and had verification by the reference standard • Miscarriage, fetal abnormalities and multiple pregnancies were regarded as legitimate exclusions Inadequate
• -90% of the participants originally subjected to the screening tests were followed up Unreported
• It was not possible to draw a conclusion based on the information reported in the article Adapted from Conde-Agudelo et al., 2004 w12x. PEspre-eclampsia.
LRq )10 and LR--0.1 w11, 12x. On the other hand, tests with LRq -5 or LR-)0.2 achieve only minimal prediction and the other tests achieve moderate prediction w12x. We followed the PRISMA guidelines w22x in order to maximize the quality of the report of our systematic review.
Results
Figure 1 depicts the results of each stage of the selection process. According to the selection criteria previously described, 35 articles were eligible and, of those, three w34, 36, 37x reported results of the same cohort. Therefore, 33 studies were reviewed, which are described in Table 3 .
Twenty-one cohort and 12 nested case-control studies were included. Seven were conducted in high-risk populations, defined by the presence of risk factors for PE in the maternal history, an abnormal second-trimester UAD or high secondtrimester levels of human chorionic gonadotropin (hCG) and alpha-fetoprotein (AFP).
Studies of low-risk populations reported a prevalence of PE that varied between 1.2% and 10.5%, although it was F3.0% in the majority. Those which evaluated screening for early PE reported a prevalence of this outcome of 0.3-0.8%, with the exception of one study which reported a prevalence of 2.3%.
The conclusions of some studies are limited by the size of their samples, which is partly related to the low frequency of PE and especially early PE in the general population. For example, six studies included only F10 participants with early PE. Screening tests were performed in the first trimester in 12 studies, in the second trimester in 15 studies and in both trimesters in six studies.
Maternal history was evaluated in 16 studies, pregnancyassociated plasma protein-A (PAPP-A) in 11 studies, inhibin A in nine studies, placental growth factor (PlGF) in eight studies, hCG, activin A and placental protein 13 (PP13) in six studies each, soluble fms-like tyrosine kinase 1 (sFlt1) in four studies and MAP and AFP in three studies each.
It should be noted that some studies are related. Seven w1-3, 30, 33-35x were conducted as part of the same research program and had overlapping study groups. This also happened in two additional studies w27, 50x. To avoid data duplication, whenever a screening test was evaluated in more than one of these studies, we only reported its performance in the study with the largest sample. Other studies w40, 42-44x also had common participants, but we considered them separately because they evaluated different screening tests. Figure 2 presents the results of the assessment of the risk of bias. Selection of the study participants was generally adequate, but occasionally inadequate or unreported. The study population was adequately described in nearly all studies, whereas description of the screening tests was frequently inadequate because the selected cut-off points were not specified. Blinding of the readers of the screening tests was usually adequate, but sometimes unreported. On the other hand, complete blinding of the readers of the reference standard was accomplished in only two studies and was inadequate or unreported in the remaining. Follow-up and verification was adequate in most studies but in several it was unreported.
Tables 4-7 summarize the results of each study. The performance of screening tests is reported quantitatively, through AUC, Sp, Sn, LRq and LR-, and qualitatively, through a citation of the article. Figures 3 and 4 show the screening tests that provided moderate or convincing prediction, according to the LR values. None of the screening tests for late PE qualified. A few screening tests for total PE were moderately predictive, all of which involved second-trimester testing. On the other hand, screening for early PE was accomplished with moderate accuracy by several first-and second-trimester tests. Additionally, four tests were on the averge of providing convincing prediction, and one first-trimester test was highly predictive.
Discussion Best first-trimester screening tests for early PE
Our results suggest that, in the first trimester, accurate screening for early PE probably requires the combination of several markers. Two tests that combined UAD with four other markers had a very good performance. The combination of mean PI (M-PI), maternal history, MAP, PAPP-A and PlGF was highly predictive of early PE, in a nested case-control study with almost 30 cases of early PE w33x. Of the 33 studies reviewed, one included the same number of early PE cases and only six included a higher number. Unfortunately, there were additional cases of early PE in the original cohort who did not have available serum for the measurement of PlGF and thus were not included in the case-control study. Although selection of cases was simply based on serum availability, we cannot be certain that the sample is representative of the original population. We conclude that these results are very encouraging but require confirmation by future studies.
The other test combined lowest-PI (L-PI), maternal history, PAPP-A, inhibin A and PlGF, and was applied to a cohort of nulliparous women w8x. However, it should be considered with caution because the cohort included only four participants who subsequently developed early PE. Furthermore, the authors reported that L-PI was not significantly different between the PE and normal outcome groups and that it did not improve screening by maternal history combined with the three serum markers.
Several other tests had a good performance in the first trimester, virtually all of them with a LRq )8.6 and a LR-F0.18. The majority took into account the maternal history. Other markers frequently considered were MAP, PAPP-A, inhibin A and PlGF. In particular, we would like to highlight that screening with L-PI, maternal history, MAP and PAPP-A achieved a LRq of 9.46 and a LR-of 0.06, in a cohort of over 8300 women, including 37 with early PE w34, 36, 37x.
One study w25x also achieved promising results with the combination of M-PI and PP13, albeit in a sample that included only 10 early PE cases. These results are supported by other studies, which demonstrated that first-trimester PP13 is a significant predictor of early PE w2x and that it improves screening with first-w21x and second-trimester UAD w41x. However, one study did not confirm the predictive accuracy of PP13 w8x.
Best second-trimester screening tests for early PE
Screening for early PE in the second trimester probably requires the combination of fewer markers, as UAD alone is substantially more accurate when performed in this trimester w11x.
The association of M-PI, maternal history and MAP almost provided convincing prediction in a cohort of over 3000 women, including 23 with early PE w26x. The same promising results were obtained when maternal history and first-trimester UAD were combined with the assessment of the ratio between M-PI in the second and first trimesters, in a cohort of similar dimensions w31x. Therefore, measurement of maternal serum markers may not be necessary to provide accurate screening for PE in the second trimester, because the combination of UAD with the simple and inexpensive evaluation of maternal history and MAP may be sufficient.
In women with abnormal second-trimester UAD, sFlt1 appeared to be useful in early PE screening. In one study w14x, sFlt1 provided moderate prediction and the sFlt1/PlGF ratio almost provided a convincing prediction. A similar study w46x demonstrated a good performance of the two serum markers when they were concurrently measured, but not combined in a ratio. However, both studies were limited by the size of their samples, which included only eight and nine women with early PE, respectively. Moreover, their results were challenged by a larger study, which found that sFlt1 was not able to predict early PE in a group of women with abnormal UAD w15x.
In one second-trimester study w40x, combination of UAD and PP13, with or without other serum markers, achieved moderate prediction of early PE (LRqs5, LR-s0). However, this was a case-control study which included only five cases of early PE that were selected from a cohort on the basis of serum availability. Furthermore, the authors reported that the addition of PP13 to UAD did not improve screening.
Best screening tests for late and total PE
In contrast with early PE, none of the tests were even moderately predictive of late PE. On the other hand, prediction of total PE was accomplished with moderate accuracy by some tests, all of which involved second-trimester screening and combined UAD with inhibin A, activin A, PlGF and/or sFlt1.
What to screen? Early vs. late PE
The performance of screening tests was consistently and substantially better in the prediction of early PE, compared to late PE. Our results support the concept that these are distinct disease entities w20, 48x, with impaired placentation and defective angiogenesis being related especially to early PE w13, 14, 45x, and cardiovascular and metabolic risk factors probably leading to late PE w45x. Although much less frequent than the late form of the condition w20x, early PE is the main contributor to the maternal and perinatal morbidity and mortality seen in PE w1, 31x, as it is associated with premature delivery, a higher risk of IUGR, more severe maternal disease and a higher rate of pregnancy-related maternal death w20, 48x. Considering its impact, the low incidence of early PE should not prevent routine screening. Moreover, trisomy 21, for which screening is currently performed, is even less frequent, affecting only 0.14% of newborns in the absence of any intervention w24x.
When to screen? First vs. second-trimester screening
Even though UAD is more accurate in the second trimester w11x, we found encouraging results for first-trimester screening when it was combined with other markers. We believe that screening for PE is most relevant in the first trimester because, as suggested by a recent meta-analysis w10x, preventive interventions are more likely to be effective if initiated early in pregnancy, when pathogenic mechanisms can still be modified.
Who to screen? Low vs. high-risk populations
Three studies evaluated the performance of screening tests in high-risk populations characterized by the presence of certain risk factors in the maternal history. Screening a preselected high-risk population is of particular interest, when the condition screened is infrequent, as is the case of early PE. Assuming that the Sn and Sp of the screening test remain constant, the positive predictive value increases when it is applied to a population with higher disease prevalence.
Interestingly, however, the accuracy of screening tests was consistently lower in the previously mentioned studies than in studies of low-risk populations. In nulliparous women w8x, the performance of screening with L-PI and maternal history was poorer than in unselected pregnancies w34, 36, 37x. In women with risk factors, such as chronic hypertension, pregestational diabetes mellitus and obesity, screening with M-PI and maternal history w19x or with M-PI and PP13 w21x was also less predictive than in low-risk populations w25, 31x.
In the meta-analysis performed by Cnossen et al. w11x , screening with the PI was less accurate in high-risk populations. Thus, our results may be explained by the lower performance of UAD in women with historical risk factors.
They further support the concept of PE as a heterogeneous disease w13, 38, 48x and suggest that, in these women, impaired placentation may play a less important role in the development of PE w19x.
Limitations of the reviewed studies
Several studies that we reviewed were limited by the size of their samples and by the risk of bias in certain methodological areas.
Selection of study participants was occasionally inadequate. Some nested case-control studies included only a subset of PE cases of the original cohort because only those had available blood samples for the measurement of specific markers. Additionally, some cohort studies did not apply the screening tests to all eligible participants.
Outcome assessors were not completely blinded to the results of the screening tests in several studies. In some cases, blinding was inadequate because the results of UAD influenced the subsequent management of pregnancies. In other cases, investigators evaluated screening for PE with firsttrimester PAPP-A or hCG, or with second-trimester hCG or AFP, and had to communicate the results of the screening tests to pregnant women and their managing clinicians because they were necessary for routine assessment of trisomy 21 risk. This shows that, at times, although the methodology of the study may lead to bias, it is the best that researchers are able to do, and for that reason the PRISMA statement w22x recommends that the term ''quality'' be replaced by ''risk of bias''. The comparison of individual studies is limited by differences observed among them, concerning, for example, the definitions of PE and early PE and the UAD technique.
Although, in the studies reviewed, the definitions of PE always included the concurrent presence of hypertension and proteinuria, we identified among them several differences. Concerning hypertension, some studies considered it to be present when either the systolic (SBP) or diastolic blood pressure (DBP) was elevated, while others did so only in the presence of high DBP. Generally, the diagnosis of hypertension required at least two recordings of elevated BP with a minimal 4-6 h interval, and cut-offs of 140 mm Hg and 90 mm Hg were considered for high SBP and DBP, respectively. Occasionally, however, studies reported the presence of hypertension when DBP was G110 mm Hg on any occasion or G90 mm Hg on at least two occasions. Proteinuria was usually defined as protein excretion of G300 mg in a 24-h urine collection, but two dipstick readings of G2q, or occasionally G1q, were also frequently considered diagnostic if no 24-h collection was available.
The definition of early PE was also not uniform and almost one-third of the studies did not report screening for this outcome.
The technical performance of UAD was usually, but not always, clearly reported. Investigators used color Doppler to identify the uterine arteries (UA) and pulsed wave Doppler to obtain the flow velocity waveforms. In the first trimester, UAD was generally performed using a transabdominal approach. In the second trimester, transabdominal UAD was also used, but the transvaginal approach was more frequent, often because investigators concurrently measured the cervical length for the assessment of the risk of premature delivery. In the majority of studies, waveforms were obtained from the UA at the level of the internal cervical os, but in several others they were obtained at or 1 cm distal to the crossover point with the external iliac artery. Investigators variably required an angle of insonation below 308, 508 or 608, and several did not describe it. Although PI was most frequently reported, some studies evaluated other Doppler parameters, such as the resistance index or the presence of early diastolic notches.
Limitations and strengths of our review
The strength of our conclusions is limited by the multiplicity of combinations evaluated, the variability of the gestational age at which tests were performed (even within the same trimester) and the diversity of populations studied. Additionally, as in any review, it is limited by the shortcomings of the original studies, which we have previously discussed.
On the other hand, our review has several strengths: we used explicit and reproducible methodology, we minimized the risk of bias using rigorously predefined selection criteria and a standardized data extraction form, we assessed the risk of bias of the included studies with objective criteria, we reported the findings of each study and summarized those findings in a systematic way.
Our review does not provide definitive conclusions, but rather highlights important advances that have been made in PE screening and offers guidance and optimism for future research. To our knowledge, it is the first review that systematically evaluates the combination of UAD, maternal history, MAP and serum markers in the prediction of PE.
While screening for total and especially late PE remains disappointing, we have demonstrated encouraging results in the prediction of early PE. In addition to the eight serum markers we reviewed, others, such as soluble endoglin and homocysteine, might be useful when combined with UAD.
We believe that future research should focus on first-trimester screening for early PE, with a combination of UAD, maternal history, MAP, and serum markers, such as PAPP-A, inhibin A and PlGF. Large cohort studies are needed in order to accurately study this relatively infrequent outcome of pregnancy.
